GLP-1 drugs and disordered eating: separating signal from noise

What's this video probably claiming?

Based on the hashtag combination of glp1, disorderedeating, and realisticnutrition, this video is almost certainly wading into one of the thorniest conversations currently happening in weight-loss medicine: whether GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro, Zepbound) are appropriate, helpful, or potentially harmful for people with a history of disordered eating. The creator likely frames this as a personal or community-level reckoning, possibly arguing that these drugs either silence the obsessive food noise that drives restrictive or binge eating patterns, or alternatively, that they risk reinforcing restriction and triggering relapse in people with anorexia or orthorexia histories. Both framings get significant traction in nutrition-creator spaces, and both contain real clinical substance worth scrutinizing.

What does the science actually show?

The honest answer is: not enough, and what exists is genuinely mixed. The STEP trials for semaglutide and SURMOUNT trials for tirzepatide excluded participants with active eating disorders, which means we have almost no randomized controlled trial data on this population. What we do have are mechanistic studies and smaller observational reports. Giel et al. (2023, European Eating Disorders Review) noted that GLP-1 agonists reduce "food noise" partly by acting on hypothalamic reward circuitry, which could theoretically reduce obsessive food preoccupation seen in binge eating disorder. Separately, Konttinen et al. (2019, International Journal of Eating Disorders) flagged that appetite suppression drugs in people with restrictive eating histories may compound caloric deficits to dangerous levels. Tirzepatide at 15 mg produced mean weight loss of 20.9% over 72 weeks in SURMOUNT-1, which is a substantial physiological shift that a fragile relationship with food and body image may not tolerate well.

Where does the social media noise diverge from clinical reality?

The loudest TikTok narrative right now is that GLP-1 drugs are "healing" disordered eating by removing the mental burden of food decisions. This is a real phenomenon for some patients, and there is preliminary data from Himmerich et al. (2023, CNS Drugs) suggesting GLP-1 pathways interact with dopaminergic reward systems in ways relevant to compulsive eating. But "food noise reduction" is not the same as treating an eating disorder, and conflating them is where creators cause real harm. Clinically, binge eating disorder, bulimia nervosa, and anorexia nervosa are distinct psychiatric conditions requiring structured treatment. A GLP-1 drug that suppresses appetite does not address cognitive distortions, trauma, or the behavioral cycles underlying these disorders. The secondary risk, almost never discussed in these videos, is that nausea-driven restriction, which is a common GLP-1 side effect affecting roughly 30-40% of users in the STEP trials, can feel rewarding to someone with a restrictive eating history in ways that accelerate relapse.

What should you actually know?

If you have a current or historical eating disorder diagnosis, a conversation about GLP-1 therapy requires a multidisciplinary team, not just a prescriber. The Eating Disorders Coalition and multiple clinical guidelines now explicitly recommend psychiatric and dietitian clearance before initiating GLP-1 therapy in this population. That is not overcaution; it reflects real case report literature showing relapse in patients with remitted anorexia after starting semaglutide. On the other side, for binge eating disorder specifically, there is growing interest in GLP-1 agents as adjuncts. Wilding et al. (2021, NEJM) data and subsequent analyses suggest reduced binge frequency in some patients, though again, this was not a primary endpoint and the population was not specifically selected for BED diagnosis. The bottom line: this is a legitimate clinical conversation, the science is genuinely early, and any creator presenting certainty in either direction is outpacing the evidence.